High prevalence of metabolic syndrome in patients with psoriasis in Lebanon: a prospective study

Itani, Salam; Arabi, Asma; Harb, Dana; Hamzeh, Diana; Kibbi, Abdul‐Ghani

doi:10.1111/ijd.12811

Cited by 31 publications

(44 citation statements)

References 28 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With the inclusion of seven new studies published from July 1, 2016- January 1, 2017, the unadjusted odds ratios for metabolic syndrome in psoriasis patients ranged from 0.84–6.09, and the adjusted odds ratios ranged from 1.22–5.14. When stratified by disease severity, the prevalence of metabolic syndrome demonstrated a dose-dependent relationship with the degree of psoriasis severity [30, 37, 40, 56, 61, 62, 68]. For example, the adjusted odds ratio for metabolic syndrome in severe psoriasis was 1.98, while in mild psoriasis it was 1.22 [37].…”

Section: Resultsmentioning

confidence: 99%

An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies

2017

View full text Add to dashboard Cite

The relationship between psoriasis and metabolic syndrome is not well understood. Though multiple epidemiologic studies have suggested a link between psoriasis and metabolic syndrome, there is a lack of a comprehensive meta-analysis synthesizing the results of all available observational studies to date. In this meta-analysis, we examined global data on the relationship between psoriasis and odds of metabolic syndrome by searching for studies published between 1946–2016. Specifically, we analyzed the results from 35 observational studies from 20 countries with 1,450,188 total participants, of which 46,714 were psoriasis patients. The pooled odds ratio based on random effects analysis was 2.14 (95% CI 1.84–2.48). Publication bias was present, as evidenced by an Egger test and graphical visualization through a funnel plot (p = 0.001). Based on this comprehensive meta-analysis, psoriasis patients have higher odds of having metabolic syndrome when compared with the general population.

show abstract

Section: Resultsmentioning

confidence: 99%

An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies

2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Recently, psoriasis has come to be considered a multisystem disease linked to different comorbidities like cardiovascular diseases and associated risk factors such as metabolic syndrome. 6,[25][26][27] In the literature, up to 25% of patients requiring systemic therapy can be affected by these risk factors. 28 As a consequence of this, severe psoriasis is associated with increased risk of myocardial infarction, stroke, cardiovascular death, and overall mortality.…”

Section: Discussionmentioning

confidence: 99%

Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Whereas, the opposite situation was noted when comparing the diabetic and nondiabetic patients. Observations conducted by two independent research teams indicate that systemic diseases concurrent with psoriasis contribute to more intensified psoriatic symptoms (Itani, Arabi, Harb, Hmazeh, & Kibbi, ; Meziane et al, ). It may result from the disproportion between the number of patients with Diabetes 2 when compared with the number of patients without it.…”

Section: Discussionmentioning

confidence: 99%

“…Whereas, the opposite situation was noted when comparing the diabetic and nondiabetic patients. Observations conducted by two independent research teams indicate that systemic diseases concurrent with psoriasis contribute to more intensified psoriatic symptoms (Itani, Arabi, Harb, Hmazeh, & Kibbi, 2016;Meziane et al, 2016 Gisondi, Del Giglio, and Di Francesco (2008) states that in the group of obese psoriatic patients treated using CsA, reduced body weight (through the use of a low-calorie diet) improves response to the medicine.…”

Section: Discussionmentioning

confidence: 99%

The impact of diabetes and metabolic syndromes to the effectiveness of cyclosporine a pharmacotherapy in psoriatic patients

Michalska-Bańkowska

Grabarek

Wcisło‐Dziadecka

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Metabolic diseases concurrent with psoriasis may considerably affect the intensity of its symptoms and therapy efficacy. Cyclosporine A (CsA) is one of the medicines used in conventional therapy of psoriasis. The aim of the study was to determine whether Diabetes 2 and metabolic syndromes influence the efficacy of the CsA therapy in psoriatic patients. The sample group was composed of 32 patients with diagnosed moderate to severe forms of psoriasis vulgaris. The group was divided into subgroups, with regard to concurrently occurring Diabetes 2 and metabolic syndromes. The subgroups were composed of as follows: with diabetes—7 patients, without diabetes—25, with metabolic syndrome—15, without concurrent metabolic syndrome—17, with a metabolic syndrome without diabetes—8 and with both a metabolic syndrome and diabetes—7 patients. The efficacy of therapy was evaluated in each subgroup on the basis of the following scales: PASI, BSA, DLQI on the day of therapy commencing, after 42 and 84 days of the CsA therapy. The statistical analysis was performed with the use of STATISICA 12 (Cracow, Poland; p < .05). The following tests were used: The ANOVA Friedeman test, the posthoc test for ANOVA Friedeman test, the Mann–Whitney U test. We observed clinical improvement measured with PASI BSA scales in each subgroup. The patients themselves also reported improved comfort in their lives, which is confirmed by the lower score in the DLQI scale after 42 and 84 days of the pharmacotherapy. Differences in the values of each scale in a given subgroup turned to be statistically significant. The biggest differences occur after the first 42 days of therapy and they last in the later period of observations. We did not determine any statistically significant differences as a response to treatment in the subgroups subject to comparison. Diabetes and a metabolic syndrome concurrent with psoriasis vulgaris do not affect the efficacy of CsA therapy, which indicates no necessity to modify the standard dosage of the medicine and therapy regime.

show abstract

High prevalence of metabolic syndrome in patients with psoriasis in Lebanon: a prospective study

Abstract: This was the first study to assess the prevalence of MBS in Lebanese subjects with psoriasis and, to our knowledge, the first study that showed a higher likelihood of MBS in patients with inverse psoriasis and with nail pitting.

Cited by 31 publications

References 28 publications

An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies

An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies

Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries

The impact of diabetes and metabolic syndromes to the effectiveness of cyclosporine a pharmacotherapy in psoriatic patients

Contact Info

Product

Resources

About